CFTR and cystic fibrosis: Until recently, elexacaftor–tezacaftor–ivacaftor (ETI) was approved only for individuals with cystic fibrosis (CF) who carried at least one copy of the Phe508del mutation, the most common CFTR mutation in Caucasian populations.